GLP-1 Tirzepatide Reviewhttps://glp1tirzepatidereview.comIndependent evidence, pricing and provider research on tirzepatide and GLP-1 care.en-us2026-07-24FDA Proposes Permanent Exclusion of Semaglutide, Tirzepatide and Liraglutide From the 503B Bulks Listhttps://glp1tirzepatidereview.com/news/fda-503b-bulks-exclusion-proposal/https://glp1tirzepatidereview.com/news/fda-503b-bulks-exclusion-proposal/2026-07-24The agency found no clinical need for outsourcing facilities to compound these drugs from bulk substances. If finalised, it closes the last pathway for compounding at scale.Comment Period on the GLP-1 Bulks Proposal Extended to 30 Julyhttps://glp1tirzepatidereview.com/news/fda-comment-period-extension-503b/https://glp1tirzepatidereview.com/news/fda-comment-period-extension-503b/2026-07-24FDA granted a 60-day extension after a request for more time. The window now closes days from publication, with no final determination in sight.FDA Sends 25 More Warning Letters Over Compounded GLP-1 Marketing Claimshttps://glp1tirzepatidereview.com/news/fda-25-warning-letters-june-2026/https://glp1tirzepatidereview.com/news/fda-25-warning-letters-june-2026/2026-07-24The June letters continue a pattern running back to September 2025, and the target is consistent: what providers say their product is.FDA Approves Foundayo (Orforglipron), the First Small-Molecule Oral GLP-1 for Weight Losshttps://glp1tirzepatidereview.com/news/foundayo-orforglipron-fda-approval/https://glp1tirzepatidereview.com/news/foundayo-orforglipron-fda-approval/2026-07-24A once-daily pill with no food or water restrictions, available from $149 a month self-pay — and the lowest mean weight reduction of any approved option.FDA Approves the Wegovy Pill: Oral Semaglutide 25 mg for Weight Managementhttps://glp1tirzepatidereview.com/news/wegovy-pill-oral-semaglutide-approval/https://glp1tirzepatidereview.com/news/wegovy-pill-oral-semaglutide-approval/2026-07-24The first oral GLP-1 approved for weight loss, with cardiovascular risk reduction on the label and results close to the injectable.STEP UP: Semaglutide 7.2 mg Reports 20.7% Weight Loss, Narrowing the Gap With Tirzepatidehttps://glp1tirzepatidereview.com/news/step-up-semaglutide-7-2mg/https://glp1tirzepatidereview.com/news/step-up-semaglutide-7-2mg/2026-07-24A threefold increase on the approved dose brings semaglutide close to tirzepatide's SURMOUNT-1 figure — if tolerability holds.Medicare GLP-1 Bridge Opens: $50 a Month for Eligible Part D Enrolleeshttps://glp1tirzepatidereview.com/news/medicare-glp1-bridge-launches/https://glp1tirzepatidereview.com/news/medicare-glp1-bridge-launches/2026-07-24For the first time Medicare covers GLP-1s for weight loss — through a demonstration programme that expires at the end of 2027 with no confirmed successor.CMS Delays the BALANCE Model Indefinitely and Extends the GLP-1 Bridge Insteadhttps://glp1tirzepatidereview.com/news/balance-model-part-d-delayed/https://glp1tirzepatidereview.com/news/balance-model-part-d-delayed/2026-07-24The programme meant to succeed the Bridge has been postponed without a new date, leaving temporary access with nothing confirmed behind it.TrumpRx Launches Direct GLP-1 Pricing, Undercutting List Prices by Up to Nine Timeshttps://glp1tirzepatidereview.com/news/trumprx-launch-direct-pricing/https://glp1tirzepatidereview.com/news/trumprx-launch-direct-pricing/2026-07-24A direct-to-consumer channel advertising semaglutide tablets from $149 and tirzepatide injections from $299, against list prices above $1,000.NovoCare Cuts Wegovy Self-Pay Pricing to $349 From $499https://glp1tirzepatidereview.com/news/novocare-wegovy-price-cut/https://glp1tirzepatidereview.com/news/novocare-wegovy-price-cut/2026-07-24A 30% reduction on the manufacturer's direct channel, and part of a broader repricing that has reshaped the affordability argument.SOUL: Oral Semaglutide Cuts Major Cardiovascular Events by 14% in High-Risk Type 2 Diabeteshttps://glp1tirzepatidereview.com/news/soul-trial-oral-semaglutide-cardiovascular/https://glp1tirzepatidereview.com/news/soul-trial-oral-semaglutide-cardiovascular/2026-07-24A 9,647-patient outcomes trial reporting a 14% reduction in MACE and 22% in heart failure events — a hard-endpoint result in a field dominated by surrogate measures.EVOKE and EVOKE+: Oral Semaglutide Made No Difference to Alzheimer's Progressionhttps://glp1tirzepatidereview.com/news/evoke-alzheimers-null-result/https://glp1tirzepatidereview.com/news/evoke-alzheimers-null-result/2026-07-24A 3,808-patient, two-year programme returned a null result — and null results in this field deserve more coverage than they get.REIMAGINE 2: CagriSema Beats Semaglutide on HbA1c by 1.91 Points With 14.2% Weight Losshttps://glp1tirzepatidereview.com/news/reimagine-2-cagrisema-diabetes/https://glp1tirzepatidereview.com/news/reimagine-2-cagrisema-diabetes/2026-07-24The furthest-advanced next-generation combination reports in type 2 diabetes, ahead of an FDA response expected during 2026.SYNCHRONIZE-1: 16.6% Weight Loss With 34% Less Visceral Fat and 63% Less Liver Fathttps://glp1tirzepatidereview.com/news/synchronize-1-visceral-liver-fat/https://glp1tirzepatidereview.com/news/synchronize-1-visceral-liver-fat/2026-07-24A 76-week phase 3 readout measuring where fat is lost, not only how much — which is the more clinically informative question.ACCESS II: A Second Oral Small-Molecule GLP-1 Posts 16.3% Placebo-Adjusted Weight Losshttps://glp1tirzepatidereview.com/news/structure-therapeutics-oral-access-ii/https://glp1tirzepatidereview.com/news/structure-therapeutics-oral-access-ii/2026-07-24Structure Therapeutics reports phase 2 results with no fasting window required — a direct challenge to oral semaglutide's administration burden.FDA Advisory Committee Reviews BPC-157, TB-500 and Five Other Peptides This Weekhttps://glp1tirzepatidereview.com/news/fda-peptide-advisory-committee-july-2026/https://glp1tirzepatidereview.com/news/fda-peptide-advisory-committee-july-2026/2026-07-24Briefing documents posted in June recommended against adding any of the seven to the 503A compounding list. The committee met on 23 and 24 July.Sandoz and Amneal File for Generic Tirzepatide — But Lilly's Patents Run to 2036https://glp1tirzepatidereview.com/news/generic-tirzepatide-anda-filings/https://glp1tirzepatidereview.com/news/generic-tirzepatide-anda-filings/2026-07-24An ANDA filing is the start of a legal process, not an imminent launch. Anything sold as generic tirzepatide today is not one.FDA Signals It Will Restrict GLP-1 Active Ingredients Used in Non-Approved Compounded Productshttps://glp1tirzepatidereview.com/news/fda-february-2026-api-restriction/https://glp1tirzepatidereview.com/news/fda-february-2026-api-restriction/2026-07-24The February announcement was the turn from warning letters to structural action, and the bulks proposal followed twelve weeks later.The Tirzepatide Shortage Delisting Was Not One Date — It Was a Year of Litigationhttps://glp1tirzepatidereview.com/news/tirzepatide-shortage-timeline-litigation/https://glp1tirzepatidereview.com/news/tirzepatide-shortage-timeline-litigation/2026-07-24Widely reported as 'October 2024', the delisting was determined, remanded, contested and re-affirmed across five months. We had it wrong too.A 2026 Study Finds Tirzepatide and B12 Can Chemically Bond — Forming a Molecule Not in the Approved Drughttps://glp1tirzepatidereview.com/news/compounded-b12-chemical-bonding-study/https://glp1tirzepatidereview.com/news/compounded-b12-chemical-bonding-study/2026-07-24Additives used to differentiate compounded products from their approved counterparts are largely untested, and at least one interacts.SURMOUNT-5 Published: Tirzepatide 20.2% Against Semaglutide 13.7% in the First Head-to-Headhttps://glp1tirzepatidereview.com/news/surmount-5-published-nejm/https://glp1tirzepatidereview.com/news/surmount-5-published-nejm/2026-07-24751 adults, 72 weeks, maximum tolerated doses of each — the only trial that has compared these two drugs directly for weight management.SUMMIT: Tirzepatide Cuts Worsening Heart-Failure Events by 38% in Obesity-Related HFpEFhttps://glp1tirzepatidereview.com/news/summit-hfpef-results/https://glp1tirzepatidereview.com/news/summit-hfpef-results/2026-07-24A 731-patient phase 3 trial in a specific cardiac phenotype, with imaging substudies supporting a mechanical explanation.Three Years of Tirzepatide Markedly Reduced Progression to Type 2 Diabetes in Prediabeteshttps://glp1tirzepatidereview.com/news/surmount-1-three-year-diabetes-prevention/https://glp1tirzepatidereview.com/news/surmount-1-three-year-diabetes-prevention/2026-07-24The longest published follow-up in this field: 1,032 participants, 176 weeks of treatment, and a hard clinical endpoint rather than a surrogate.Zepbound Now Carries an Obstructive Sleep Apnoea Indication Alongside Weight Managementhttps://glp1tirzepatidereview.com/news/zepbound-osa-indication/https://glp1tirzepatidereview.com/news/zepbound-osa-indication/2026-07-24The first GLP-1 approved for a sleep disorder, following the SURMOUNT-OSA programme — and a coverage implication for patients whose plans exclude weight management.GLP-1 Use Reaches 11% of US Adults as the Obesity Rate Falls to 36.4%https://glp1tirzepatidereview.com/news/gallup-glp1-use-obesity-decline/https://glp1tirzepatidereview.com/news/gallup-glp1-use-obesity-decline/2026-07-24Current use has nearly quadrupled in two years. Over the same period national obesity prevalence declined from its 2022 peak.ADA 2026: Adding a Myostatin Inhibitor Cut the Lean-Mass Share of Weight Loss From 21% to 7%https://glp1tirzepatidereview.com/news/ada-2026-bimagrumab-lean-mass/https://glp1tirzepatidereview.com/news/ada-2026-bimagrumab-lean-mass/2026-07-24The first strong signal that the composition of GLP-1 weight loss is pharmacologically modifiable — with a large gap still open on function.ADA 2026: Semaglutide Improved Knee Osteoarthritis Pain — and Tirzepatide's Extra Weight Loss Did Not Add Morehttps://glp1tirzepatidereview.com/news/ada-2026-osteoarthritis-outcomes/https://glp1tirzepatidereview.com/news/ada-2026-osteoarthritis-outcomes/2026-07-24Meaningful WOMAC reduction and less analgesic use, with an asymmetry that raises a question about mechanism.The Wegovy Pill Passed Three Million Prescriptions in Just Over Five Monthshttps://glp1tirzepatidereview.com/news/wegovy-pill-three-million-prescriptions/https://glp1tirzepatidereview.com/news/wegovy-pill-three-million-prescriptions/2026-07-24An uptake rate suggesting the oral route addressed a real barrier rather than offering a marginal alternative.Semaglutide Came Off the Shortage List in February 2025 — With a May Deadline for Outsourcing Facilitieshttps://glp1tirzepatidereview.com/news/semaglutide-shortage-resolved-enforcement/https://glp1tirzepatidereview.com/news/semaglutide-shortage-resolved-enforcement/2026-07-24The delisting closed the pathway that had permitted compounding at scale, on a defined wind-down timetable.A Major Telehealth Platform Withdrew a Compounded Copy of the Wegovy Pill Under Legal Threathttps://glp1tirzepatidereview.com/news/hims-compounded-wegovy-pill-withdrawal/https://glp1tirzepatidereview.com/news/hims-compounded-wegovy-pill-withdrawal/2026-07-24The episode is widely cited as the point at which FDA enforcement shifted focus from compounders to the platforms marketing them.